Induced pluripotent stem cells: advances to applications

Timothy J Nelson1, Almudena Martinez-Fernandez1, Satsuki Yamada1, Yasuhiro Ikeda2, Carmen Perez-Terzic1, Andre Terzic11Marriott Heart Disease Research Program, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA; 2Department of Molecular Medicine; Mayo Clinic, Rochester, Minn...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Timothy J Nelson, Almudena Martinez-Fernandez, Satsuki Yamada, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Cytology QH573-671
Acceso en línea:	https://doaj.org/article/da3eac8fe3174e628788242439bc6189
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:da3eac8fe3174e628788242439bc6189
record_format	dspace
spelling	oai:doaj.org-article:da3eac8fe3174e628788242439bc61892021-12-02T04:41:31ZInduced pluripotent stem cells: advances to applications1178-6957https://doaj.org/article/da3eac8fe3174e628788242439bc61892009-12-01T00:00:00Zhttp://www.dovepress.com/induced-pluripotent-stem-cells-advances-to-applications-a3857https://doaj.org/toc/1178-6957Timothy J Nelson1, Almudena Martinez-Fernandez1, Satsuki Yamada1, Yasuhiro Ikeda2, Carmen Perez-Terzic1, Andre Terzic11Marriott Heart Disease Research Program, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA; 2Department of Molecular Medicine; Mayo Clinic, Rochester, Minnesota, USAAbstract: Induced pluripotent stem cell (iPS) technology has enriched the armamentarium of regenerative medicine by introducing autologous pluripotent progenitor pools bioengineered from ordinary somatic tissue. Through nuclear reprogramming, patient-specific iPS cells have been derived and validated. Optimizing iPS-based methodology will ensure robust applications across discovery science, offering opportunities for the development of personalized diagnostics and targeted therapeutics. Here, we highlight the process of nuclear reprogramming of somatic tissues that, when forced to ectopically express stemness factors, are converted into bona fide pluripotent stem cells. Bioengineered stem cells acquire the genuine ability to generate replacement tissues for a wide-spectrum of diseased conditions, and have so far demonstrated therapeutic benefit upon transplantation in model systems of sickle cell anemia, Parkinson&rsquo;s disease, hemophilia A, and ischemic heart disease. The field of regenerative medicine is therefore primed to adopt and incorporate iPS cell-based advancements as a next generation stem cell platforms.Keywords: iPS, regenerative medicine, individualized medicine, stem cell therapy Timothy J NelsonAlmudena Martinez-FernandezSatsuki Yamadaet alDove Medical PressarticleCytologyQH573-671ENStem Cells and Cloning: Advances and Applications, Vol 2010, Iss default, Pp 29-37 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Cytology QH573-671
spellingShingle	Cytology QH573-671 Timothy J Nelson Almudena Martinez-Fernandez Satsuki Yamada et al Induced pluripotent stem cells: advances to applications
description	Timothy J Nelson1, Almudena Martinez-Fernandez1, Satsuki Yamada1, Yasuhiro Ikeda2, Carmen Perez-Terzic1, Andre Terzic11Marriott Heart Disease Research Program, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA; 2Department of Molecular Medicine; Mayo Clinic, Rochester, Minnesota, USAAbstract: Induced pluripotent stem cell (iPS) technology has enriched the armamentarium of regenerative medicine by introducing autologous pluripotent progenitor pools bioengineered from ordinary somatic tissue. Through nuclear reprogramming, patient-specific iPS cells have been derived and validated. Optimizing iPS-based methodology will ensure robust applications across discovery science, offering opportunities for the development of personalized diagnostics and targeted therapeutics. Here, we highlight the process of nuclear reprogramming of somatic tissues that, when forced to ectopically express stemness factors, are converted into bona fide pluripotent stem cells. Bioengineered stem cells acquire the genuine ability to generate replacement tissues for a wide-spectrum of diseased conditions, and have so far demonstrated therapeutic benefit upon transplantation in model systems of sickle cell anemia, Parkinson&rsquo;s disease, hemophilia A, and ischemic heart disease. The field of regenerative medicine is therefore primed to adopt and incorporate iPS cell-based advancements as a next generation stem cell platforms.Keywords: iPS, regenerative medicine, individualized medicine, stem cell therapy
format	article
author	Timothy J Nelson Almudena Martinez-Fernandez Satsuki Yamada et al
author_facet	Timothy J Nelson Almudena Martinez-Fernandez Satsuki Yamada et al
author_sort	Timothy J Nelson
title	Induced pluripotent stem cells: advances to applications
title_short	Induced pluripotent stem cells: advances to applications
title_full	Induced pluripotent stem cells: advances to applications
title_fullStr	Induced pluripotent stem cells: advances to applications
title_full_unstemmed	Induced pluripotent stem cells: advances to applications
title_sort	induced pluripotent stem cells: advances to applications
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/da3eac8fe3174e628788242439bc6189
work_keys_str_mv	AT timothyjnelson inducedpluripotentstemcellsadvancestoapplications AT almudenamartinezfernandez inducedpluripotentstemcellsadvancestoapplications AT satsukiyamada inducedpluripotentstemcellsadvancestoapplications AT etal inducedpluripotentstemcellsadvancestoapplications
_version_	1718401155040542720

Induced pluripotent stem cells: advances to applications

Ejemplares similares